Important information
The information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the United States or any other country where the offer or sale of subscription rights, interim shares or new shares is not permitted. The information may not be published or distributed, directly or indirectly, in or into, any of the aforementioned countries or any other country where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. Nor may the information be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or gives cause to such requirements. Failure to comply with these instructions may result in a violation of the United States Securities Act of 1933, as amended (“Securities Act”) or laws applicable in other jurisdictions.

The information in this press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Hansa Medical AB. No subscription rights, interim shares or new shares will be registered under the Securities Act or in accordance with any other rules or regulations in any other country than Sweden and may not be transferred or offered for sale in the United States or any country where such transfer or offer may be prohibited, or to persons resident in any such country or on account of such persons, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act or similar legislation in another country, respectively.

Hansa Medical’s shares admitted to trading on Nasdaq Stockholm

Nasdaq Stockholm’s listing committee has admitted the shares of Hansa Medical AB (publ) to trading on Nasdaq Stockholm’s main market. The first day of trading is planned to fall on November 2, 2015.

The resolution to admit Hansa Medical’s shares to trading is conditional upon the company fulfilling certain formal requirements, inter alia in relation to a prospectus and education.

The listing on Nasdaq Stockholm’s main market means that Hansa Medical’s listing on First North Premier ceases. The last trading day in the company’s share on First North Premier will be October 30, 2015. The company’s shareholders do not need to take any action because of the listing.

Hansa Medical has applied for approval and registration of a prospectus drafted due to the listing. It is expected to approved, registered and published on or around October 26, 2015.

The listing is not combined with any issue, sale or any other offering to the market.

Fredersen Advokatbyrå AB has acted as legal advisor.

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical
Hansa Medical

- PRESS RELEASE -
October 22, 2015

development). The company is based in Lund, Sweden. Hansa Medical’s share (HMED) is listed on First North Premier in Stockholm with Remium Nordic AB as Certified Adviser.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on October 22, 2015 at 08.00 CET.